Tablet press investment at Juniper Pharma Services
![](/46/pdcnewsitem/04/14/05/Ian%20L.jpg)
Ian Lafferty at Juniper Pharma Services
Latest addition to the company's suite of tablet manufacturing equipment enables the CDMO to produce single and bi-layer tablets in multiple tooling formats.
Juniper Pharma Services has bolstered its tablet manufacturing capabilities following the purchase and validation of an additional tablet press.
The investment by the UK-based contract development and manufacturing organisation (CDMO) significantly extends its tablet production capacity and further strengthens the company’s ability to support clients’ clinical needs.
Its new RoTab tablet press by kg-pharma is designed specifically for batch sizes from 50g to 50kg and allows Juniper Pharma Services to produce up to 42,000 tablets per hour. This latest addition to its suite of tablet manufacturing equipment enables the CDMO to produce single and bi-layer tablets in multiple tooling formats.
The tablet press is the latest in a string of recent equipment investments by the CDMO and comes just weeks after the company announced significant expansion to its spray drying, topical, and semi-solid capabilities.
Ian Lafferty, VP of operations at Juniper Pharma Services, said: “The installation of this additional tablet press machine takes both our capability to produce different tablet types, and our output capacity, to a new level.
“This fully instrumented machine provides real time compression data, allowing our team to provide invaluable understanding during the optimisation of clients’ tablet formulations, enabling a smooth transition from pilot scale to commercial high speed tablet manufacturing.”
Juniper Pharma Services develops and produces oral and topical drug products for clinical trials and is able to optimise formulation performance through its team’s science-led approach to projects.
Dr Lafferty added: “We continue to expand our support to pharmaceutical and biotechnology companies across the globe, especially to those with significant formulation challenges requiring the integrated skills of a problem-to-solution minded development team.
“Our recent investments have strategically expanded and extended our development and manufacturing capabilities to ensure we are equipped to support drug development at a clinical scale, while also giving a commercially robust and replicable process.”
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance